In another placebo-controlled, phase II trial, NASH resolution with no worsening of fibrosis was reported in 59% of patients receiving 0.4 mg of the GLP-1 analogue semaglutide versus 17% in the placebo group (p < 0.001); however, no significant improvement of fibrosis was observed between groups [144]. Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.